Health Science Reports · 2023 · 31 citations · 21 references
MedicineMolecular MedicineOncologyMolecular OncologyPrecision MedicinePrecision OncologyCancer PharmacogenomicsCancer Precision MedicineLung Cancer PharmacotherapyPersonalized Cancer TherapyPersonalized Treatment PlanningTargeted Cancer TherapyCost Savings AnalysisCost Savings EvaluationPersonalized Cancer MedicinePersonalized Cancer TreatmentPersonalized Medicine ImplementationPrecision Medicine ApplicationsPrecision Oncology ApplicationsPrecision Therapeutics
Background: Precision medicine (PM) is a form of personalized medicine that recognizes that individuals with the same condition may have different underlying factors and uses molecular information to provide tailored treatments. This approach can improve treatment outcomes and transform lives through favorable risk/benefit ratios, avoidance of ineffective interventions, and possible cost savings, as evidenced in the field of lung cancer and other oncology/therapeutic settings, including cardiac disease, diabetes, and rare diseases. However, the potential benefits of PM have yet to be fully realized. Discussion: There are many barriers to the implementation of PM in clinical practice, including fragmentation of the PM landscape, siloed approaches to address shared challenges, unwarranted variation in availability and access to PM, lack of standardization, and limited understanding of patients' experience and needs throughout the PM pathway. We believe that a diverse, intersectoral multistakeholder collaboration, with three main pillars of activity: generation of data to demonstrate the benefit of PM, education to support informed decision-making, and addressing barriers across the patient pathway, is necessary to reach the shared goal of making PM an accessible and sustainable reality. Besides healthcare providers, researchers, policymakers/regulators/payers, and industry representatives, patients in particular must be equal partners and should be central to the PM approach-from early research through to clinical trials and approval of new treatments-to ensure it represents their entire experience and identifies barriers, solutions, and opportunities at the point of delivery. Conclusion: We propose a practical and iterative roadmap to advance PM and call for all stakeholders across the healthcare system to employ a collaborative, cocreated, patient-centered methodology to close gaps and fully realize the potential of PM.
21
Integrating Genomics into Healthcare: A Global Responsibility
Zornitza Stark, Lena Dolman, Teri A. Manolio et al. · The American Journal of Human Genetics · 2019 · 395 citations · Full text
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
Daphne van der Velden, Louisa R. Hoes, Hanneke van der Wijngaart et al. · Nature · 2019 · 269 citations · Full text
Medicine, Oncology, Pharmacology +10
Wendy K. Chung, Karel Erion, José C. Florez et al. · Diabetologia · 2020 · 195 citations · Full text